Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Clinigen Group PLC    CLIN   GB00B89J2419

CLINIGEN GROUP PLC (CLIN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Clinigen : boost unlicensed drugs business with Quantum takeover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 09:57am CET

Britain's Clinigen Group on Wednesday agreed to buy Quantum Pharma for 150.3 million pounds, bringing together two companies that specialise in the supply of unlicensed medicines to doctors and hospitals.

Clinigen said the deal would accelerate its global ambitions in the ethical supply of unlicensed medicines - drugs that are either in clinical trials or are licensed in other markets - to doctors who want to use them for their patients.

Chief Executive Shaun Chilton said it would also increase its ability to convert unlicensed drugs into licensed products.

"(Quantum) introduces an unlicensed medicine in the initial stages to cope with an unmet need and it converts it into a licensed medicine," he said in an interview.

"That unlicensed-to-licensed piece acts as a bridge between two of our business operations: our unlicensed medicines division and our commercial medicines division."

Quantum shareholders will receive 37 pence in cash and 0.0405 new Clinigen shares for each share, valuing each Quantum share at 82 pence, Clinigen said.

Quantum, which installed a new management team in October 2016 after a period of underperformance, reported revenue from continuing operations of 36.2 million pounds for the six months to end-July and adjusted core earnings of 5.7 million pounds.

Shares in Quantum rose 17.5 percent to 78 pence in early deals. Clinigen was trading down 1.4 percent.

(Reporting by Paul Sandle; editing by Jason Neely)

Stocks treated in this article : Clinigen Group PLC, Quantum Pharma PLC
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLINIGEN GROUP PLC
11/22 CLINIGEN : registers Garsun® (artesunate for injection) in South Africa for the ..
11/22 CLINIGEN : Registers Garsun® (artesunate for injection) in South Africa for the ..
11/10 CLINIGEN : Issue of Equity
11/10 CLINIGEN : Form 8.3 - Clinigen Group PLC
11/10 CLINIGEN : Neuberger Berman Group LLC - Form 8.3 - Clinigen Group PLC
11/09 CLINIGEN GROUP PLC : ex-dividend day for final dividend
11/06 CLINIGEN : Scheme of arrangement becomes effective
11/06 Clinigen group plc. - board changes
11/01 MITON GROUP PLC : - Form 8.3 - Clinigen Group Plc
10/27 CLINIGEN : Neuberger Berman Group LLC - Form 8.3 - Clinigen Group PLC
More news
News from SeekingAlpha
09/28 Clinigen Group reports FY results
03/15 Clinigen Group reports Q4 results
2016 Clinigen Group reports FY16 results
2016 Clinigen acquires chemo reversing agent from Biocodex
2016 Clinigen Group PLC reports 1H16 results
Financials ( GBP)
Sales 2018 374 M
EBIT 2018 71,1 M
Net income 2018 39,9 M
Debt 2018 81,6 M
Yield 2018 0,55%
P/E ratio 2018 30,45
P/E ratio 2019 23,90
EV / Sales 2018 3,54x
EV / Sales 2019 2,97x
Capitalization 1 244 M
Chart CLINIGEN GROUP PLC
Duration : Period :
Clinigen Group PLC Technical Analysis Chart | CLIN | GB00B89J2419 | 4-Traders
Technical analysis trends CLINIGEN GROUP PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 11,7  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Shaun Edward Chilton Chief Executive Officer & Executive Director
Peter Vance Allen Non-Executive Chairman
Debra Ainge Chief Operating Officer
Martin Abell Chief Financial Officer & Executive Director
Ivo Timmermans Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CLINIGEN GROUP PLC43.38%1 658
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS4.73%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731